RCS - Aptamer Group PLC - Aptamer Presenting at ASGCT Annual Meeting

AptamerAnnouncement

29/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250429:nRSc5154Ga&default-theme=true

RNS Number : 5154G  Aptamer Group PLC  29 April 2025

 

29 April 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Aptamer Presenting at ASGCT Annual Meeting

 

New Data on Optimer® Delivery Vehicle Targeting Fibrotic Liver

 

Aptamer Group plc (AIM: APTA), the leading developer of next generation
synthetic binders delivering innovation to the life science industry, today
announces that it will present new data showcasing its proprietary Optimer®
delivery vehicle targeting fibrotic liver at the upcoming 2025 American
Society for Gene and Cell Therapy (ASGCT) Annual Meeting, to be held from 13 -
17 May 2025 in New Orleans, Louisiana.

 

Dr David Bunka, Aptamer's Chief Scientific Officer, will present the latest
advances regarding Aptamer's proprietary Optimer® delivery vehicle,
demonstrating its precision-targeting capabilities for fibrotic liver disease
- a major unmet clinical need with significant commercial potential.  The new
data will show how the Optimer® delivery vehicle enables targeted delivery of
RNAi therapies specifically to activated hepatic stellate cells, the key
drivers of liver fibrosis.

 

Current gene therapies face well-documented barriers in achieving
cell-specific targeting, intracellular uptake, and endosomal escape. Optimer®
delivery vehicles are designed to overcome each of these challenges, unlocking
new possibilities for effective, tissue-specific gene therapies across a wide
range of chronic diseases.

 

This targeted delivery technology has the potential to enhance therapeutic
efficacy, reduce off-target effects, and broaden the clinical utility of gene
therapies, addressing a critical barrier in RNAi drug development.

Presentation details

Title: Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using
Aptamers: A Novel Approach for Fibrotic Liver Treatment

Session Title: Oligonucleotide Therapeutics (including siRNAs, aptamers,
antagomirs, miRNAs, shRNA, antisense, splice switching oligos, plasmids)

Session Date and Time: Wednesday, 14 May 2025, 5:30 pm - 7:30 pm

Location: New Orleans Ernest N. Morial Convention Center, New Orleans, USA

Abstract Presentation Number: 1147

Presenting Author: Dr David Bunka, Aptamer Group, Windmill House, Innovation
Way, York, YO10 5BR, UK

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

Aptamer Group is a leading developer of next generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

 

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAIPMLTMTJTBAA